Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


13 Items
Title  Creator  Group name  Publishing year 
Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery Houvenaeghel et al. EquipeCTCS 2024-09-27
Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery Houvenaeghel et al. EquipeCTCS 2023-09-14
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors Mangiardi-Veltin et al. EquipeCTCS 2022-06
Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study Houvenaeghel et al. EquipeCTCS 2022-11
[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)] Gligorov et al. EquipeCTCS 2020-05
Corrigendum to 'clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome' Scholl et al. EquipeCTCS 2020-07
Tubular and mucinous breast cancer: results of a cohort of 917 patients Roux et al. EquipeCTCS 02/2019
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact Houvenaeghel et al. EquipeCTCS Jan 2019
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome Scholl et al. EquipeCTCS May 2019
Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit de Nonneville et al. EquipeCTCS Jun 2019
Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB) Houvenaeghel et al. EquipeCTCS Aug 2017
[Breast cancer screening: On our way to the future] Delaloge et al. EquipeCTCS 09 2016
HER2-positive breast cancer: ¹?F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy Humbert et al. EquipeELC Aug 2014
13 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés